DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
P••••••• P••••• B••
Pharmaceuticals, Biotechnology & Life Sciencesgroup grade Aoff every schedule since Mar 31, 2024sponsor unattributed
Nothing material in the last 200 days. Last change: 31 Mar 2024, Consensus mark 96¢ on cost, down from 97¢ a year ago, 99¢ last quarter.
Mark path, consensus per quarter end
97¢ · 98¢ · 94¢ · 99¢ · 96¢Q1 2023 to Q1 2024
Principal held
at least $10.5M
sum of BDC pieces, a lower bound
Fair value
$11.4M
96c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
2
0 equity pieces beside them
Next maturity
Feb 1, 2026
$10.5M inside 24 months
On the tape since
Dec 31, 2022
latest Mar 31, 2024
Events
3
dated, non-routine
Lender marks
each lender's own fair value over cost at Mar 31, 2024, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| C••••••• C•••••• B••• I••• | $10.5M | 96¢ | -3 pts |
Every BDC piece · 3 positions across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| C••••••• C•••••• B••• I••• | term loan first lien Investment T••• U••••••••• F•••• L••• - L••• Out T••• L••• I••••••• T••• E + 625 I••••••• | $6.9M | $7.5M 96c | S+625 bp |
| C••••••• C•••••• B••• I••• | delayed draw term loan first lien Investment T••• U••••••••• F•••• L••• D•••••• D••• T••• L••• I••••••• T••• E + 625 I•••••• | $1.9M | $2.0M 93c | S+625 bp |
| C••••••• C•••••• B••• I••• | delayed draw term loan first lien Investment T••• U••••••••• F•••• L••• D•••••• D••• T••• L••• I••••••• T••• E + 625 I•••••• | $1.7M | $1.9M 100c | S+625 bp |
Capital structure as the BDCs see it
latest quarter end Mar 31, 2024
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Mar 31, 2024 | at least $6.9M | 96c | S+625 bp | Feb 1, 2026 | 1 |
| first lien delayed draw term loan first lien exited Mar 31, 2024 | at least $3.6M | 96c | S+625 bp | Feb 1, 2026 | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2024 | 1 | $10.5M | $11.4M | 96c | 0 |
| Dec 31, 2023 | 1 | $10.5M | $11.6M | 99c | 0 |
| Sep 30, 2023 | 1 | $10.5M | $11.1M | 94c | 0 |
| Jun 30, 2023 | 1 | $10.5M | $11.5M | 98c | 0 |
All 6 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2023 | 1 | $11.4M | $11.4M | 97c | 0 |
| Dec 31, 2022 | 1 | $9.2M | $9.8M | 96c | 0 |
What changed
- Facility left every BDC scheduleMar 31, 2024
- Facility left every BDC scheduleMar 31, 2024
- New borrower on a BDC scheduleDec 31, 2022
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- PHARCOMP #NLderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Pharmaceuticals, Biotechnology & Life Sciencesreportedas one filer wrote it